Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
July 30, 2019
Assignee:
Genentech, Inc.
Inventors:
Carlos Bais, Matthew Brauer, Mallika Singh, Maike Schmidt
Abstract: The present application relates to compositions of humanized and deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to anti-endoglin antibodies which inhibit or treat fibrosis.
Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
Type:
Grant
Filed:
January 30, 2018
Date of Patent:
June 25, 2019
Assignee:
Teva Pharmaceuticals International GmbH
Inventors:
Joerg Zeller, Kristian Todd Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of ischemic conditions. In particular, the present invention relates to a method of treating an ischemic condition in a subject in need thereof comprising administering the subject with a polypeptide comprising an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino acid residue at position 186 to the amino acid residue at position 406 in SEQ ID NO: 1.
Type:
Grant
Filed:
January 6, 2016
Date of Patent:
June 18, 2019
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), COLLEGE DE FRANCE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP), ECOLE NATIONALE VETERINAIRE D'ALFORT (ENVA)
Abstract: The invention relates to an anti-CGRP antibody for use in the prevention and/or treatment of chronic pain and/or symptoms of chronic pain, and to a method of treating and/or preventing chronic pain and/or symptoms of chronic pain using an anti-CGRP antibody.
Type:
Grant
Filed:
May 2, 2018
Date of Patent:
June 18, 2019
Assignee:
Teva Pharmaceuticals International GmbH
Inventors:
Kristian Todd Poulsen, David Louis Shelton, Joerg Zeller, Ian Machin, Laura Corradini
Abstract: The invention provides compositions and methods for treating a disease or disorder associate with vascular endothelial growth factor (VEGF). Specifically, the invention relates to an oligomerized VEGF binding domain to provide VEGF antagonism, and thereby treat diseases associated thereof.
Type:
Grant
Filed:
July 25, 2016
Date of Patent:
June 4, 2019
Assignee:
GENZYME CORPORATION
Inventors:
James Stefano, Clark Pan, Huawei Qiu, Michael O'Callaghan, Gloria Matthews
Abstract: Provided is a liquid formulation that enables the stable storage of recombinant fusion proteins, comprising a recombinant fusion protein, a buffer salt, a stabilizer, and a surfactant.
Abstract: Disclosed herein are isolated polypeptides capable of preventing collapsin response mediator protein 2 (CRMP2)-small ubiquitin-like modifier (SUMO)ylation mediated trafficking of voltage gated sodium channel 1.7 (Nav1.7) function. In some examples, the disclosed peptides comprise three to twenty amino acids and include the amino acid sequence KMD. Also disclosed are methods of decreasing nociception including administering an effective amount of one or more disclosed peptides to a subject in need thereof, such as a subject experiencing chronic pain.
Type:
Grant
Filed:
March 6, 2015
Date of Patent:
May 14, 2019
Assignee:
THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
Inventors:
Rajesh Khanna, May Khanna, Todd W. Vanderah, Erik T. Dustrude
Abstract: The disclosure relates to methods for treating a subject suffering from hyperalgesia caused by drug-induced neuropathy by administering to the subject an effective amount of an aromatic-cationic peptide. The disclosure also relates to methods for protecting a subject from hyperalgesia caused by drug-induced neuropathy by administering an effective amount of an aromatic-cationic peptide to a subject at risk for developing the condition.
Abstract: Provided are chimeric VEGF-binding proteins and nucleic acids (e.g., a vector) encoding chimeric VEGF-binding proteins, methods and host cells for producing these proteins and nucleic acids, and pharmaceutical compositions containing these proteins and nucleic acids. Also provided are methods of treating an angiogenic disease or disorder that include administering at least one of the chimeric VEGF-binding proteins or at least one of the nucleic acids (e.g., a vector) encoding a chimeric VEGF-binding protein.
Type:
Grant
Filed:
June 12, 2017
Date of Patent:
April 16, 2019
Assignees:
Children's Medical Center Corporation, The General Hospital Corporation, President and Fellows of Harvard College
Inventors:
Bob Carter, Jeng-Shin Lee, Szofia S. Bullain, Richard C. Mulligan
Abstract: A fusion polypeptide capable of binding simultaneously to angiopoietin 2, VEGF-C and VEGF-D; or capable of binding simultaneously to VEGF-C and VEGF-D, and methods for the preparation and use thereof.
Type:
Grant
Filed:
August 2, 2017
Date of Patent:
April 2, 2019
Assignee:
SAMSUNG ELECTRONICS CO., LTD.
Inventors:
Kwang Hoon Lee, Hyung-Chan Kim, Sang Yeul Han, Seok Kyun Kim, Kyung Eun Kim
Abstract: The invention relates to producing humoral response to P2X7 receptors in individuals having cancer, and to minimizing the progression of cancer in said individuals.
Type:
Grant
Filed:
January 5, 2017
Date of Patent:
April 2, 2019
Assignee:
BIOSCEPTRE (AUST) PTY LTD
Inventors:
Julian Alexander Barden, Angus Gidley-Baird
Abstract: The invention relates to the identification of a novel epitope on non-function P2X7 receptors which are implicated in cancer. The epitope includes a region from two adjacent monomers within the three subunit receptor. Antibodies which bind to the epitope and peptides for generating the antibodies are described. The antibodies and peptides are useful in the diagnosis and treatment of cancer.
Type:
Grant
Filed:
March 30, 2016
Date of Patent:
March 26, 2019
Assignee:
BIOSCEPTRE (AUST) PTY LTD
Inventors:
Julian Alexander Barden, Angus Gidley-Baird
Abstract: Antibodies and antibody fragments thereof with binding specificity to human Nerve Growth Factor (NGF) and methods of use for treating pain. Methods of treating pain or eliciting an analgesic effect comprising administering an effective amount of an anti-human NGF antibody or antibody fragment thereof, which inhibits the association of NGF with TrkA, and/or p75. These methods may optionally further comprising administering an effective amount of a second anti-human NGF antibody or fragment thereof (e.g., one which inhibits the association of NGF with p75, or one that inhibits the association of NGF with TrkA.
Type:
Grant
Filed:
July 20, 2017
Date of Patent:
March 12, 2019
Assignee:
ALDERBIO HOLDINGS LLC
Inventors:
Leon F. Garcia-Martinez, John Latham, Ethan W. Ojala, Corinne C. Akatsuka, Pei Fan, Jeffrey T. L. Smith, Benjamin H. Dutzar
Abstract: This invention pertains to NGF antagonists including antibodies and fragments thereof (including Fab fragments) having binding specificity to human Nerve Growth Factor (hereinafter “NGF”), and methods of using one or more of said antibodies and fragments thereof to treat pain in an individual. More specifically the invention relates to methods of treating pain or eliciting an analgesic effect in an individual, comprising administering an effective amount of an NGF antagonist, e.g., an anti-human NGF antibody or fragment thereof or another moiety, such as a nucleic acid or polypeptide such as a fragment of NGF or TrkA which inhibits the association of NGF with TrkA, without appreciably inhibiting the association of NGF with p75. These methods may optionally further include administering an effective amount of a second anti-human NGF antibody or fragment thereof which inhibits the association of NGF with p75, that may further also inhibit the association of NGF with TrkA.
Type:
Grant
Filed:
May 2, 2016
Date of Patent:
March 5, 2019
Assignee:
Alderbio Holdings LLC
Inventors:
John A. Latham, Ethan W. Ojala, Jeffrey T. L. Smith, Benjamin H. Dutzar, Leon F. Garcia-Martinez
Abstract: Endoglin has been identified to play a functional role as a regulator of TGF?1 signaling, particular in TGF?1-mediated calcineurin expression. The present invention features methods of reducing cardiac damage, particularly in a subject undergoing chemotherapy or radiation therapy by administering a composition that inhibits endoglin activity. The present invention also features methods of treating autoimmune diseases, inflammatory diseases, organ transplantation, and conditions association with oxidative stress related to TGF?1-mediated calcineurin expression and reactive oxygen species (ROS) production by administering a composition that inhibits endoglin activity. The present invention also features methods of treating fibrotic diseases by administering a composition that inhibits endoglin activity.
Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.